Pricing Log in Create free account
Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

192.51 14.86 +8.36%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revolution Medicines, Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

Red flags

  • Short cash runway

    Revolution Medicines, Inc.’s cash and short-term investments cover about 1.6 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 11.9% in a year, to 216.3 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 48 added · 39 removed · 37 modified; 4 with only figures updated; 1 moved without change